MEDRONATE DISODIUM

Details

Stereochemistry	ACHIRAL
Molecular Formula	CH4O6P2.2Na
Molecular Weight	219.9659
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[Na+].OP([O-])(=O)CP(O)([O-])=O

InChI

InChIKey=RXSYPQBNTPQOTQ-UHFFFAOYSA-L

InChI=1S/CH6O6P2.2Na/c2-8(3,4)1-9(5,6)7;;/h1H2,(H2,2,3,4)(H2,5,6,7);;/q;2*+1/p-2

HIDE SMILES / InChI

Molecular Formula	CH4O6P2
Molecular Weight	173.9864
Charge	-2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/018124s013lbl.pdf
Curator's Comment: Description was created based on several sources, including: https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=9635

Medronic acid (conjugate base, medronate) is a diagnostic agent that is used in complex with technetium Tc-99m for imaging delineate areas of altered osteogenesis. Upon administration the complex binds to hydroxyapatite crystals in bone.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Hydroxyapatite crystals in bone 5 Target ID: Hydroxyapatite crystals in bone Sources: https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=9635	Binding Agent 1064

Conditions

Condition	Modality	Targets	Highest Phase	Product
Altered osteogenesis 7 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/018124s013lbl.pdf	Diagnostic		Approved 8429	CIS-MDP Approved Use Technetium Tc 99m Medronate Injection may be used as a bone imaging agent to delineate areas of altered osteogenesis. Launch Date 1979

PubMed

Title	Date	PubMed
Cytosolic acidification as a signal mediating hyperosmotic stress responses in Dictyostelium discoideum.	2001	11415467
Plasmacytoma of the temporal bone: management with a combination of surgery and radiotherapy.	2001 Dec	11813894
Determination of the casein content in bovine milk by 31P-NMR.	2002 Aug	12369412
Aspartyl phosphonates and phosphoramidates: the first synthetic inhibitors of bacterial aspartate-semialdehyde dehydrogenase.	2002 Sep 2	12210989
Effect of technetium-99 conjugated with methylene diphosphonate on IgM-RF, IgG-RF and IgA-RF.	2003	14526429
Escherichia coli response to exogenous pyrophosphate and analogs.	2003	12673060
Complexation of beryllium(II) ion by phosphinate ligands in aqueous solution. Synthesis and XRPD structure determination of Be[(PhPO2)2CH2](H2O)2.	2003 Apr 7	12665369
Isoprenoid biosynthesis via the MEP pathway. Synthesis of (3,4)-3,4-dihydroxy-5-oxohexylphosphonic acid, an isosteric analogue of 1-deoxy-D-xylulose 5-phosphate, the substrate of the 1-deoxy-D-xylulose 5-phosphate reducto-isomerase.	2003 Dec 21	14685307
Effectory site in Escherichia coli inorganic pyrophosphatase is revealed upon mutation at the intertrimeric interface.	2003 Jan	12716061
Follow-up of collagen crosslink excretion in patients with oral squamous cell carcinoma and analysis of tissue samples.	2003 Nov 3	14583776
Gelatin sheet incorporating basic fibroblast growth factor enhances sternal healing after harvesting bilateral internal thoracic arteries.	2003 Oct	14566256
Solid state coordination chemistry: one-, two-, and three-dimensional materials constructed from molybdophosphonate subunits linked through binuclear copper tetra-2-pyridylpyrazine groups.	2003 Oct 20	14552625
[A comparison of planar scintigraphy and MRI in the screening of skeletal metastases].	2003 Sep	14661604
Shoulder girdle neoplasms mimicking frozen shoulder syndrome.	2003 Sep-Oct	14564266
Bone lesion detection with carrier-added 99mTc-EDTMP in comparison with 99mTc-DPD.	2004 Apr	15097810
Efficient synthesis of protected cyclopropyl beta-aspartylphosphates.	2004 Feb 21	14770233
Some processes of energy saving and expenditure occurring during ethanol perfusion in the isolated liver of fed rats; a Nuclear Magnetic Resonance study.	2004 Mar 1	15053831
Synthesis of acyloxymethyl ester prodrugs of the transferable protein farnesyl transferase substrate farnesyl methylenediphosphonate.	2004 Oct 4	15341963
Voltammetry as a virtual potentiometric sensor in modelling of a metal-ligand system and refinement of stability constants. Part 4. An electrochemical study of NiII complexes with methylene diphosphonic acid.	2005 Dec	16213588
Effects of radiosynovectomy with p-32 colloid therapy in hemophilia and rheumatoid arthritis.	2005 Jun	15989482
Technetium-99m diphosphonate imaging of psammocarcinoma of probable ovarian origin: case report and literature review.	2005 Jun	15891291
[A cationic cluster of amino acid residues of inorganic pyrophosphatase from Escherichia coli as a possible site of effector binding].	2005 May-Jun	16004383
Biochemical and imaging alterations of renal bone disease in newly detected predialysis and on maintenance dialysis patients.	2005 Oct	16223439
Synthesis and antiviral evaluation of alkoxyalkyl esters of phosphonopropoxymethyl-guanine and phosphonopropoxymethyl-diaminopurine.	2006	17042330
Usefulness of 18F-FDG PET-directed skeletal biopsy for metastatic neoplasm.	2006 Aug	16843854
Monoglycosyl, diglycosyl, and dinucleoside methylenediphosphonates: direct synthesis and antiviral activity.	2006 Jul 3	16618481
Cytotoxic and genotoxic effects induced by stannous chloride associated to nuclear medicine kits.	2006 Oct	17045172
Growth modification of the mandible with ultrasound in baboons: a preliminary report.	2006 Oct	17045140
Metastatic pulmonary calcification in a dialysis patient: case report and a review.	2006 Oct	17022753
Three-level bilateral pediculolysis following osteoporotic lumbar compression fracture.	2006 Sep-Oct	16934724
Safety considerations with bisphosphonates for the treatment of osteoporosis.	2007	17722968
Photo-induced lipid peroxidation of erythrocyte membranes by a bis-methanophosphonate fullerene.	2007 Dec	17686607
Metabolic fingerprints of altered brain growth, osmoregulation and neurotransmission in a Rett syndrome model.	2007 Jan 17	17237885
Effect of age and gender on the number and distribution of sites in Paget's disease of bone.	2007 Jul	17646188
Bisphosphonate rescue in distraction osteogenesis: a case series.	2007 Jun	17513972
Ewing's sarcoma of the third metatarsal: a case report and review of the literature.	2007 Mar-Apr	17557573

Patents

Sample Use Guides

In Vivo Use Guide

The suggested dose range of Technetium Tc 99m Medronate Injection in the average adult patient (70 kg) is 370-740 megabecquerels: (10-20 millicuries) given intravenously.

Route of Administration: Intravenous

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:19:56 GMT 2023` Edited by `admin` on `Fri Dec 15 15:19:56 GMT 2023`
Record UNII	HAY5MT18L3
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MEDRONATE DISODIUM

Official Name

English

DISODIUM MEDRONATE

Common Name

English

Medronate disodium [WHO-DD]

Common Name

English

PHOSPHONIC ACID, P,P'-METHYLENEBIS-, SODIUM SALT (1:2)

Systematic Name

English

MEDRONATE DISODIUM [MART.]

Common Name

English

SODIUM METHYLENEDIPHOSPHONATE

Systematic Name

English

PHOSPHONIC ACID, METHYLENEBIS-, DISODIUM DIHYDROGEN SALT

Common Name

English

Disodium dihydrogen methylenediphosphonate

Systematic Name

English

MEDRONATE DISODIUM [II]

Common Name

English

MEDRONATE DISODIUM [VANDF]

Common Name

English

MEDRONATE DISODIUM [USAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C443